The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Open accessAbstract
BACKGROUND: Bruton's tyrosine kinase (BTK) is a mediator of the B-cell-receptor signaling pathway implicated in the pathogenesis of B-cell cancers. In a phase 1 study, ibrutinib, a BTK inhibitor, showed antitumor activity in several types of non-Hodgkin's lymphoma, including mantle-cell lymphoma. METHODS: In this phase 2 study, we investigated oral ibrutinib, at a daily dose of 560 mg, in 111 patients with relapsed or refractory mantle-cell lymphoma. Patients were enrolled into two groups: those who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles of bortezomib or had received no prior bortezomib therapy. The primary end point was the overall response rate. Secondary end points were duration of response, progression-free survival, overall survival, and safety. RESULTS: The median age was 68 years, and 86% of patients had intermediate-risk or high-risk mantle-cell lymphoma according to clinical prognostic factors. Patients had received a median of three prior therapies. The most common treatment-related adverse events were mild or moderate diarrhea, fatigue, and nausea. Grade 3 or higher hematologic events were infrequent and included neutropenia (in 16% of patients), thrombocytopenia (in 11%), and anemia (in 10%). A response rate of 68% (75 patients) was observed, with a complete response rate of 21% and a partial response rate of 47%; prior treatment with bortezomib had no effect on the response rate. With an estimated median follow-up of 15.3 months, the estimated median response duration was 17.5 months (95% confidence interval [CI], 15.8 to not reached), the estimated median progression-free survival was 13.9 months (95% CI, 7.0 to not reached), and the median overall survival was not reached. The estimated rate of overall survival was 58% at 18 months. CONCLUSIONS: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma. (Funded by Pharmacyclics and others; ClinicalTrials.gov number, NCT01236391.)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, it is not selective for BTK, and multiple mechanisms of resistance, including the C481S-BTK mutation, can compromise its efficacy.”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
In the citing paper
“often due to the C481S mutation of BTK, which prevents ibrutinib from forming a covalent bond with BTK and significantly reduces its potency, resulting in median progression-free survival of only ;14 months.8”
From Bruton tyrosine kinase degradation as a therapeutic strategy for cancer (2019) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,236
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
Swerdlow, S. H. (2017) · Medical Entomology and Zoology · Cited by 12,933
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Self-citationOptimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,456
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215637 · Cited by 2,270
Self-citationChronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
Davis, R. E., Ngo, V. N., Lenz, G., Tolar, P., Young, R. M., Romesser, P. B., Kohlhammer, H., Lamy, L., Zhao, H., Yang, Y., et al. (2010) · Nature · doi:10.1038/nature08638 · Cited by 1,651
Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.7906 · Cited by 1,128
Self-citationHerman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood · doi:10.1182/blood-2011-01-328484 · Cited by 807
Self-citation
Research works printed but not linked: 1
- 10.2307/2281868 · DOI · Paper page
Cited by
Sorted by citations
Items 801–900 of 1,000
Papaioannou, D., Nicolet, D., Özer, H. G., Mrózek, K., Volinia, S., Fadda, P., Carroll, A. J., Kohlschmidt, J., Kolitz, J. E., Wang, E. S., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1125 · Cited by 13
Tucker, D. L., Morley, N. J., MacLean, P., Vandenberghe, E., Booth, S. W., Parisi, L., & Rule, S. A. (2020) · British Journal of Haematology · doi:10.1111/bjh.16739 · Cited by 13
Self-citationIbrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma
Graf, S. A., Cassaday, R. D., Morris, K. K., Voutsinas, J. M., Wu, Q. V., Behnia, F., Lynch, R. C., Krakow, E. F., Rasmussen, H., Chauncey, T. R., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.11.023 · Cited by 13
LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome
Thurner, L., Fadle, N., Bittenbring, J. T., Regitz, E., Schuck, R., Cetin, O., Stuhr, A., Rixecker, T. M., Murawski, N., Poeschel, V., et al. (2021) · Blood · doi:10.1182/blood.2020008835 · Cited by 13
Self-citationRan, F., Liu, Y., Chen, X., Zhuo, H., Xu, C., Li, Y., Duan, X., & Zhao, G. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104968 · Cited by 13
Ibrutinib Blocks YAP1 Activation and Reverses BRAF Inhibitor Resistance in Melanoma Cells
Misek, S. A., Newbury, P. A., Chekalin, E., Paithankar, S., Doseff, A. I., Chen, B., Gallo, K. A., & Neubig, R. R. (2021) · Molecular Pharmacology · doi:10.1124/molpharm.121.000331 · Cited by 14
Sjögren’s syndrome: shedding light on emerging and key drug targets
Ridgewell, D., Thalayasingam, N., & Ng, W. (2022) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2022.2157259 · Cited by 13
Munakata, W., Ando, K., Yokoyama, M., Fukuhara, N., Yamamoto, K., Fukuhara, S., Ohmachi, K., Mishima, Y. M., Ichikawa, S., Ogiya, D., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-022-03514-6 · Cited by 13
CD52 and OXPHOS—potential targets in ibrutinib-treated mantle cell lymphoma
Fuhr, V., Heidenreich, S., Srivastava, M., Riedel, A., Düll, J., Hartmann, E., Rosenwald, A., & Rauert‐Wunderlich, H. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01289-7 · Cited by 13
Bronson, J. J., Black, A., Dhar, T. G. M., Ellsworth, B. A., & Merritt, J. R. (2014) · Annual reports in medicinal chemistry · doi:10.1016/b978-0-12-800167-7.00027-4 · Cited by 13
Ali, N., Malik, F. A., Jafri, S. I. M., Naglak, M. C., Sundermeyer, M. L., & Pickens, P. V. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.011 · Cited by 13
Badar, T., Astle, J. M., Kakar, I., Zellner, K., Hari, P., & Hamadani, M. (2020) · British Journal of Haematology · doi:10.1111/bjh.16738 · Cited by 13
Heß, G., Wagner, K., Keller, U. B., Rosée, P. G. L., Atta, J., Hübel, K., Lerchenmueller, C., Schoendube, D., Witzens‐Harig, M., Ruckes, C., et al. (2020) · HemaSphere · doi:10.1097/hs9.0000000000000398 · Cited by 13
Self-citationRole of allogeneic stem cell transplantation in mantle cell lymphoma
Cohen, J. B., Burns, L. J., & Bachanová, V. (2014) · European Journal Of Haematology · doi:10.1111/ejh.12442 · Cited by 13
Ibrutinib‐induced severe liver injury
Nandikolla, A. G., Derman, O., Nautsch, D., Liu, Q., Massoumi, H., Venugopal, S., Braunschweig, I., & Janakiram, M. (2017) · Clinical Case Reports · doi:10.1002/ccr3.881 · Cited by 13
Huang, S., Liu, Y., Chen, Z., Wang, M. L., & Jiang, C. (2022) · PubMed Central · Cited by 13
Self-citationPromising efficacy of novel BTK inhibitor AC0010 in mantle cell lymphoma
Yan, X., Zhou, Y., Huang, S., Li, X., Yu, M., Huang, J., Wang, J., Ma, Z., Jin, J., Pan, J., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-017-2570-8 · Cited by 12
Chen, Y., Yang, P., Wang, J., Gao, S., Xiao, S., Zhang, W., Zhu, M., Wang, Y., Ke, X., & Jing, H. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00381-7 · Cited by 12
Gambino, S., Quaglia, F. M., Galasso, M., Cavallini, C., Chignola, R., Lovato, O., Giacobazzi, L., Caligola, S., Adamo, A., Putta, S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-55728-9 · Cited by 12
Covalent Bruton tyrosine kinase inhibitors across generations: A focus on zanubrutinib
Broccoli, A., Re, M. D., Danesi, R., & Zinzani, P. L. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70170 · Cited by 12
Cassaday, R. D., Stevenson, P. A., Gooley, T. A., Chauncey, T. R., Pagel, J. M., Rajendran, J. G., Till, B. G., Philip, M., Orozco, J. J., Bensinger, W., et al. (2015) · British Journal of Haematology · doi:10.1111/bjh.13773 · Cited by 12
Mannina, D., & Loteta, B. (2017) · Case Reports in Hematology · doi:10.1155/2017/9583257 · Cited by 12
McCarter, S. J., Vijayvargiya, P., Sidana, S., Nault, A. M., Lane, C. E., Lehman, J. S., Wilson, J. W., Parikh, S. A., Nowakowski, G. S., & Al‐Kali, A. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1494271 · Cited by 12
Fu, S., Wang, M. L., Li, R., Lairson, D. R., Zhao, B., & Du, X. L. (2018) · Cancer Epidemiology · doi:10.1016/j.canep.2018.12.002 · Cited by 12
Self-citationGeorgantopoulos, P., Yang, H., Norris, L. B., & Bennett, C. L. (2019) · Cancer Medicine · doi:10.1002/cam4.2134 · Cited by 12
Novel Treatment Strategies in the Management of Waldenström Macroglobulinemia
Zanwar, S., Abeykoon, J. P., & Kapoor, P. (2020) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-020-00559-4 · Cited by 12
Cell Cycle Dysregulation in Mantle Cell Lymphoma
Wang, K., Huang, X., Liberto, M. D., & Chen‐Kiang, S. (2020) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2020.05.003 · Cited by 12
Mantle cell lymphoma treatment options for elderly/unfit patients: A systematic review
Alnassfan, T., Cox‐Pridmore, M. J., Taktak, A. F. G., & Till, K. J. (2021) · eJHaem · doi:10.1002/jha2.311 · Cited by 12
Rai, S., Tanizawa, Y., Cai, Z., Huang, Y., Taipale, K., & Tajimi, M. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02258-3 · Cited by 12
Efficacy and safety of ibrutinib in mantle cell lymphoma: A systematic review and meta-analysis
Roufarshbaf, M., Javeri, M., Akbari, V., Matin, P. H., Farrokhi, P., Sadeghi, E., Heidari, Z., & Moghaddas, A. (2022) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-022-00444-w · Cited by 12
Managing Ibrutinib-Intolerant Patients With B-Cell Malignancies
Munoz, J. L., Sarosiek, S., & Castillo, J. J. (2023) · The Oncologist · doi:10.1093/oncolo/oyac260 · Cited by 12
Tarnowski, D., Feder, A.-L., Trum, M., Kreitmeier, K.-G., Stengel, L., Maier, L. S., & Sag, C. M. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1190099 · Cited by 12
Novak, U., Fehr, M., Schär, S., Dreyling, M. H., Schmidt, C., Derenzini, E., Zander, T., Heß, G., Mey, U., Ferrero, S., et al. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102221 · Cited by 12
Self-citationTreatment Strategies in Mantle Cell Lymphoma
Maddocks, K. J., & Blum, K. A. (2015) · Cancer treatment and research · doi:10.1007/978-3-319-13150-4_10 · Cited by 12
Self-citationFerrero, S., Pastore, A., Scholz, C. W., Forstpointner, R., Pezzutto, A., Bergmann, L., Trümper, L. H. P., Finke, J., Keller, U. B., Ghione, P., et al. (2015) · Leukemia · doi:10.1038/leu.2015.215 · Cited by 12
Self-citationManagement of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies
Zaja, F. F., Federico, M., Vitolo, U., & Zinzani, P. L. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.825903 · Cited by 12
Potential breakthroughs with investigational drugs for hairy cell leukemia
Robak, T., Wolska, A., & Robak, P. J. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1081895 · Cited by 12
Targeting plasma cells: are we any closer to a panacea for diseases of antibody‐secreting cells?
Low, M. S. Y., Infantino, S., Grigoriadis, G., & Tarlinton, D. M. (2016) · Immunological Reviews · doi:10.1111/imr.12388 · Cited by 13
Agarwal, M., Bhurani, D., Shah, C., Sood, N., Singhal, M. K., Kamat, A., Subash, C., Mishra, S., & Nagrale, D. (2017) · Indian Journal of Medical and Paediatric Oncology · doi:10.4103/ijmpo.ijmpo_43_17 · Cited by 12
Cryptococcal meningoencephalitis in patients with mantle cell lymphoma on ibrutinib
Sun, K., Kasparian, S., Iyer, S. P., & Pingali, S. R. (2018) · ecancermedicalscience · doi:10.3332/ecancer.2018.836 · Cited by 12
Interrogating B cell signaling pathways: A quest for novel therapies for mantle cell lymphoma
Ahmed, M., Lorence, E., Wang, J., Jung, D., Zhang, L., Nomie, K. J., & Wang, M. L. (2019) · Science Signaling · doi:10.1126/scisignal.aat4105 · Cited by 12
Self-citationZhang, Q., Wang, H. Y., Liu, X., Roth, M. H., Shestov, A. A., Lee, S., Jain, K., Soderquist, C. R., Xiong, Q.-B., Ruella, M., et al. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00568 · Cited by 12
The role of Bruton’s tyrosine kinase inhibitors in the management of mantle cell lymphoma
Hanna, K. S., Campbell, M., Husak, A., & Sturm, S. (2020) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155220915956 · Cited by 12
Wu, H., Wang, J., Zhang, X., Yang, H., Wang, Y., Sun, P., Cai, Q., Xia, Y., & Liu, P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.588314 · Cited by 12
Mantle cell lymphoma—Advances in molecular biology, prognostication and treatment approaches
Silkenstedt, E., & Dreyling, M. H. (2021) · Hematological Oncology · doi:10.1002/hon.2860 · Cited by 12
Self-citationKohs, T. C. L., Olson, S. R., Pang, J., Jordan, K. R., Zheng, T. J., Xie, A., Hodovan, J., Muller, M. A., McArthur, C., Johnson, J. A., et al. (2022) · Cellular and Molecular Bioengineering · doi:10.1007/s12195-022-00723-1 · Cited by 12
Gill, H., Au, W. Y., Cheung, W., Lee, E. Y. P., & Kwong, Y. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu142 · Cited by 12
Slupsky, J. R. (2014) · Scientifica · doi:10.1155/2014/208928 · Cited by 15
Kojima, K., Maeda, A., Yoshimura, M., Nishida, Y., & Kimura, S. H. (2016) · Oncotarget · doi:10.18632/oncotarget.11904 · Cited by 12
Balsas, P., Esteve‐Arenys, A., Roldán, J., Jiménez, L., Rodríguez, V., Valero, J. G., Chamorro-Jorganes, A., de la Bellacasa, R. P., Teixidó, J., Matas‐Céspedes, A., et al. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0447-6 · Cited by 12
Numerous Ontogenetic Roads to Mantle Cell Lymphoma
Pouliou, E., Xochelli, A., Kanellis, G., Stalika, E., Sutton, L., Navarro, A., Agathangelidis, A., Dimosthenous, K., Anagnostopoulos, Α., Patsouris, E., et al. (2017) · American Journal Of Pathology · doi:10.1016/j.ajpath.2017.02.017 · Cited by 12
Role of stem cell transplant in lymphoma in the era of new drugs
Benekou, K., & Montoto, S. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000403 · Cited by 12
Maegawa, S., Chinen, Y., Shimura, Y., Tanba, K., Takimoto, T., Mizuno, Y., Matsumura‐Kimoto, Y., Kuwahara‐Ota, S., Tsukamoto, T., Kobayashi, T., et al. (2017) · Experimental Hematology · doi:10.1016/j.exphem.2017.12.006 · Cited by 12
Girard, J., Reneau, J. C., Devata, S., Wilcox, R. A., Kaminski, M. S., Mercer, J., Carty, S. A., & Phillips, T. J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s155778 · Cited by 12
Imbruvica—next big drug in B-cell cancer—approved by FDA
Guha, M. (2014) · Nature Biotechnology · doi:10.1038/nbt0214-113 · Cited by 12
Acalabrutinib for adults with mantle cell lymphoma
Jurczak, W. J., Długosz‐Danecka, M., & Wang, M. L. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1568868 · Cited by 11
Self-citationZhao, Y., Zhao, X., Duan, L., Hou, R., Gu, Y., Liu, Z., Chen, J., Wu, F., Yang, L., Le, X. C., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02076 · Cited by 11
Dreyling, M. H., Doorduijn, J., Giné, E., Jerkeman, M., Walewski, J., Hutchings, M., Mey, U., Riise, J., Trneny, M., Vergote, V. K. J., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00362-4 · Cited by 11
Self-citationMortlock, A. A., Foote, K. M., Kettle, J. G., & Aquila, B. M. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.11033-9 · Cited by 13
What is the optimal initial management of the older MCL patient?
Kluin‐Nelemans, H. C., & Doorduijn, J. K. (2017) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2017.07.006 · Cited by 11
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents
Nabrinsky, E., Danilov, A. V., & Koller, P. (2021) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-021-00605-9 · Cited by 11
Riedell, P. A., Hamadani, M., Ahn, K. W., Litovich, C., Murthy, G. S. G., Locke, F. L., Brunstein, C. G., Merryman, R. W., Stiff, P. J., Pawarode, A., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.08.014 · Cited by 11
Ribeiro, M. L., Reyes-Garau, D., Vinyoles, M., Profitós-Pelejà, N., Santos, J. C., Armengol, M., Fernández-Serrano, M., Mor, A. S., Bech‐Serra, J. J., Blecua, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1067 · Cited by 11
Arcari, A., Morello, L., Vallisa, D., Marcheselli, L., Tecchio, C., Quaglia, F. M., Tisi, M. C., Zilioli, V. R., Rocco, A. D., Perrone, T., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1961238 · Cited by 11
Hairy Cell Leukemia (HCL) and HCL Variant: Updates and Spotlights on Therapeutic Advances
Paillassa, J., Maître, E., & Troussard, X. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01285-1 · Cited by 11
PROTACs: Novel approach for cancer breakdown by breaking proteins
Memon, H., & Patel, B. M. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120577 · Cited by 11
Heini, A. D., Bacher, U., Porret, N. A., Wiedemann, G., Legros, M., Zeerleder, D. S., Seipel, K., Novak, U., Daskalakis, M., & Pabst, T. (2022) · Cells · doi:10.3390/cells11172747 · Cited by 12
Till, K. J., Abdullah, M., Alnassfan, T., Zapata, J. G., Marks, T. A., Coma, S., Weaver, D. T., Pachter, J. A., Pettitt, A. R., & Slupsky, J. R. (2023) · Scientific Reports · doi:10.1038/s41598-023-30148-3 · Cited by 11
Diagnosis and Management of Cardiovascular Effects of Bruton's Tyrosine Kinase Inhibitors
Aghel, N., Vila, R. C. B., Lui, M., Hillis, C., & Leong, D. P. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01916-4 · Cited by 12
Resistance to PRMT5-targeted therapy in mantle cell lymphoma
Long, M., Koirala, S., Sloan, S. L., Brown-Burke, F., Weigel, C., Villagomez, L., Corps, K. N., Sharma, A., Hout, I., Harper, M., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010554 · Cited by 11
Ibrutinib-associated tumor lysis syndrome in a patient with mantle cell lymphoma: A case report
Kaur, V., & Swami, A. (2016) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155216637218 · Cited by 11
McNally, G. A., Long, J. M., Brophy, L., & Badillo, M. (2015) · Journal of the Advanced Practitioner in Oncology · doi:10.6004/jadpro.2015.6.5.3 · Cited by 11
Yang, Q., Chen, L. S., Ha, M. J., Do, K.-A., Neelapu, S. S., & Gandhi, V. V. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-3135 · Cited by 11
BTK suppresses myeloma cellular senescence through activating AKT/P27/Rb signaling
Gu, C., Peng, H., Lu, Y., Yang, H., Tian, Z., Yin, G., Zhang, W., Lu, S., Zhang, Y., & Yang, Y. (2017) · Oncotarget · doi:10.18632/oncotarget.18096 · Cited by 11
Novel therapies for relapsed/refractory mantle cell lymphoma
Arora, P. C., & Portell, C. A. (2017) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2017.10.010 · Cited by 11
Molecular profiling and management of mantle cell lymphoma
Ruan, J. (2019) · Hematology · doi:10.1182/hematology.2019000011 · Cited by 11
BTK, NUTM2A, and PRPF19 Are Novel KMT2A Partner Genes in Childhood Acute Leukemia
Zerkalenkova, E., Lebedeva, S., Borkovskaia, A., Soldatkina, O., Plekhanova, O., Tsaur, G., Maschan, M. A., Maschan, A. A., Novichkova, G. A., & Olshanskaya, Y. V. (2021) · Biomedicines · doi:10.3390/biomedicines9080924 · Cited by 12
Fichtner, M. W., Spies, E., Seismann, H., Riecken, K., Engels, N., Gösch, B., Dierlamm, J., Gerull, H., Nollau, P., Klapper, W., et al. (2016) · Haematologica · doi:10.3324/haematol.2016.141929 · Cited by 11
Self-citationProfound Sinoatrial Arrest Associated with Ibrutinib
Mathur, K., Saini, A., Ellenbogen, K. A., & Shepard, R. K. (2017) · Case Reports in Oncological Medicine · doi:10.1155/2017/7304021 · Cited by 11
Vann, K. R., Pal, D., Smith, A. L., Sahar, N.-E., Krishnaiah, M., El‐Gamal, D., & Kutateladze, T. G. (2022) · Molecular Biomedicine · doi:10.1186/s43556-021-00066-9 · Cited by 11
Wei, R., Wu, Y., Jiang, S., Zhang, A., Zhang, L., Liu, L., Wang, Y., Zhang, M., Mei, H., Liu, F., et al. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01231-w · Cited by 10
Self-citationZhao, Y., Yuan, K., Hu, Q., Li, D., Liu, M., Zhang, J., Zheng, H., & Liu, L. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.105405 · Cited by 10
Jiang, C., Lee, W., Zhang, T., Jordan, A. A., Yan, F., Cai, Q., McIntosh, J. M., Vargas, J., Liu, Y., & Wang, M. L. (2024) · Biomarker Research · doi:10.1186/s40364-024-00589-7 · Cited by 10
Self-citationCeribelli, M., Tosto, F. A., Zhang, X., Melani, C. J., Roschewski, M. J., Beck, E., Klumpp-Thomas, C., Peer, C. J., Wilson, K. M., Chen, L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2413372121 · Cited by 10
Wang, W., Cai, Q., Liu, Y., Nie, L., Lee, H., Yan, F., Fei, Y., Yao, Y., Li, Y., Tan, L., et al. (2025) · Blood · doi:10.1182/blood.2024026919 · Cited by 10
Self-citationBcl-2highmantle cell lymphoma cells are sensitized to acadesine with ABT-199
Montraveta, A., Xargay‐Torrent, S., Rosich, L., López‐Guerra, M., Roldán, J., Rodríguez, V., Lee‐Vergés, E., de Frías, M., Campàs, C., Campo, E., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4230 · Cited by 10
Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib
Smith, D. D., Goldstein, L., Cheng, M. L., James, D. F., Kunkel, L., Fardis, M., Hamdy, A., Izumi, R. E., Buggy, J. J., & Clow, F. (2014) · Annals of Hematology · doi:10.1007/s00277-014-2187-9 · Cited by 10
Self-citationMussetti, A., Kumar, A. A., Dahi, P. B., Perales, M., & Sauter, C. S. (2014) · Blood Reviews · doi:10.1016/j.blre.2014.10.001 · Cited by 10
Ibrutinib for the treatment of mantle cell lymphoma
Shah, N., Hutchinson, C. V., & Rule, S. A. (2014) · Expert Review of Hematology · doi:10.1586/17474086.2014.951323 · Cited by 10
Self-citationElectrophysiologic Complications in Cancer Patients
Lee, D. H., Chandrasekhar, S. A., & Fradley, M. G. (2019) · Methodist DeBakey Cardiovascular Journal · doi:10.14797/mdcj-15-4-282 · Cited by 10
Advances in Classification and Treatment of Non-Hodgkin Lymphoma
Rule, S. A., & Johns, S. (2020) · The Cancer Journal · doi:10.1097/ppo.0000000000000462 · Cited by 10
Self-citationCharacterization of ibrutinib as a non-covalent inhibitor of SRC-family kinases
Guo, M., Dai, S., Wu, D., Duan, Y., Li, ., Qu, L., Jiang, L., Chen, Z., Chen, X., & Chen, Y. (2020) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2020.127757 · Cited by 10
How I treat and prevent venous thrombotic complications in patients with lymphoma
Schmidt, R. A., & Lee, A. Y. Y. (2021) · Blood · doi:10.1182/blood.2019003689 · Cited by 10
Nyhoff, L. E., Griffith, A. S., Clark, E. S., Thomas, J. W., Khan, W. N., & Kendall, P. L. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2000558 · Cited by 10
Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry
Tilch, M., Visco, C., Bašić‐Kinda, S., Hermine, O., Kohn, M., Besson, C., Lamure, S., Duléry, R., Ragaini, S., Eyre, T. A., et al. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000711 · Cited by 10
Self-citationPark, H. Y., Chae, M. K., Ko, J., Kikkawa, D. O., Jang, S. Y., & Yoon, J. S. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279060 · Cited by 10
Ibrutinib maintenance after frontline treatment in patients with mantle cell lymphoma
Karmali, R., Abramson, J. S., Stephens, D. M., Barnes, J. A., Winter, J. N., Ma, S., Gao, J., Kaplan, J. B., Petrich, A. M., Hochberg, E. P., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011271 · Cited by 10
Bock, A. M., Gile, J. J., Larson, M. C., Poonsombudlert, K., Tawfiq, R. K., Maliske, S. M., Maurer, M. J., Kabat, B., Paludo, J., Inwards, D. J., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00942-3 · Cited by 10
Goodstal, S. M., Lin, J., Crandall, T., Crowley, L., Bender, A. T., Pereira, A., Soloviev, M., Wesolowski, J. S., Iadevaia, R., Schelhorn, S.-E., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-47735-z · Cited by 10
Ibrutinib: from bench side to clinical implications
Grisafi, D., Maestro, A., Grumi, C., Piazzoni, L., Tirone, G., Fiore, W., Tessari, R., Gianardi, V., Gatti, M., Tasca, F., et al. (2015) · Medical Oncology · doi:10.1007/s12032-015-0669-9 · Cited by 10
Metadata
- Authors
- Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., Barrientos, J. C., Chmielowska, E., Radford, J., Stilgenbauer, S., Dreyling, M., Jedrzejczak, W. W., Johnson, P., Spurgeon, S. E., Li, L., Zhang, L., Newberry, K., Ou, Z., Cheng, N., Fang, B., McGreivy, J., Clow, F., Buggy, J. J., Chang, B. Y., Beaupre, D. M., Kunkel, L. A., & Blum, K. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Derriford Hospital (GB)
- Weill Cornell Medicine (US)
- Hackensack University Medical Center (US)
- University of Wisconsin–Madison (US)
- Jagiellonian University (PL)
- Stanford Medicine (US)
- University of Virginia (US)
- Northwell Health (US)
- Centrum Onkologii (PL)
- University of Manchester (GB)
- University Hospital Ulm (DE)
- LMU Klinikum (DE)
- Cancer Research UK (GB)
- Oregon Health & Science University (US)
- Pharmacyclics (United States) (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- ORCID
- Wang, Michael L.
- Rule, Simon
- Martin, Peter
- Goy, Andre
- Auer, Rebecca
- Kahl, Brad S.
- Jurczak, Wojciech
- Advani, Ranjana H.
- Romaguera, Jorge E.
- Williams, Michael E.
- Barrientos, Jacqueline C.
- Radford, John
- Stilgenbauer, Stephan
- Dreyling, Martin
- Johnson, Peter
- Spurgeon, Stephen E.
- Li, Lei
- Zhang, Liang
- Newberry, Kate
- Fang, Bingliang
- Chang, Betty Y.
- Blum, Kristie A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2013-08-08
- Volume
- 369
- Issue
- 6
- Pages
- 507-516
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4513941
- OpenAlex
- W2154066874
- Cited by
- 1,685
- References
- 39
- Citations by year
- 2026: 59 · 2025: 67 · 2024: 91 · 2023: 115 · 2022: 142 · 2021: 127 · 2020: 138 · 2019: 127 · 2018: 141 · 2017: 161 · 2016: 133 · 2015: 189 · 2014: 147 · 2013: 42
- FWCI
- 127.66
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Research Explorer (The University of Manchester) (submittedVersion)
- Homo Politicus (Academy of Humanities and Economics in Lodz) (submittedVersion, cc-by-nc-nd)
- Jagiellonian University Repository (Jagiellonian University) (submittedVersion, cc-by-nc-nd)
- Funders
- American Society of Hematology
- Amgen
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Gilead Sciences
- Celgene
- Massachusetts Medical Society
- Les Laboratories Pierre Fabre
- Genentech
- Pharmacyclics
- National Cancer Institute (P30CA014520)
- Janssen Biotech
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Hematology › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Clinical Neurology › CNS Lymphoma Diagnosis and Treatment
- Keywords
- ibrutinib, BTK inhibitors, mantle cell lymphoma, relapsed/refractory lymphoma, bortezomib, B cell receptor signaling, oral BTK inhibitor, overall response rate, progression-free survival, overall survival, adverse events, neutropenia
- MeSH terms
- Agammaglobulinaemia Tyrosine Kinase, Adenine, Administration, Oral, Adult, Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Piperidines, Protein-Tyrosine Kinases, Pyrazoles, Pyrimidines, Recurrence, Survival Analysis, Lymphocyte Count, Drug Resistance, Neoplasm, Lymphoma, Mantle-Cell, Protein Kinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
